Suven Life Sciences Ltd has been granted the first certificate of suitability (CEP) by the European Directorate for quality of medicines (EDQM) for its API product, tamsulosin hydrochloride.

According to the company, the CEP will simplify and make easier the registration procedures of its customers. The role of certificate of suitability is to certify the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia (EP).

The European Directorate is one of the major institutions involved in the regulation and quality control of medicinal products authorized for use in Europe. The API, for which CEP has been granted, is suitable for use in medicinal products. The CEP's are recognized by the 36 member states of the European Union and additional countries like Australia, Canada and Switzerland.